Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Phase 1 save search
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
Published: 2023-03-28 (Crawled : 09:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
zp8396 pharma positive results phase 1
Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02
Published: 2023-03-07 (Crawled : 21:00) - globenewswire.com
FRTX 4 | $0.91 1.08% 4.39% 17K
|
Manufacturing
|
| O: 71.04%
H: 0.32%
C: -49.84%
frtx-02 topline therapeutics positive results study phase 1
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Published: 2023-03-07 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
| Email alert
Add to watchlist
BICX | $0.75 -48.98% 201.91% 4.2K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
meeting trial positive results phase 1
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
CYBN | $0.3604 -1.99% 2.41% 2.2M
|
n/a
|
| O: 2.11%
H: 4.93%
C: -9.06%
cyb003 program cyb004 trial positive update psilocybin phase 1
Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study
Published: 2023-02-23 (Crawled : 16:00) - biospace.com/
SKYE | $14.81 -8.24% -8.98% 220K
|
Transportation and Warehousing
|
| O: 1.01%
H: 25.67%
C: 7.67%
sbi-100 review positive bioscience study ophthalmic emulsion phase 1
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
INZY | $4.39 -2.66% -2.73% 810K
|
Health Technology
|
| O: 45.05%
H: 5.28%
C: -16.15%
inz-701 ongoing pharma trials topline positive phase 1
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
Published: 2023-02-08 (Crawled : 13:00) - biospace.com/
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: 1.89%
H: 1.03%
C: -4.12%
cnty-101 lymphomas cd19 trial therapeutics positive phase 1
Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort
Published: 2023-01-31 (Crawled : 15:20) - biospace.com/
SKYE | $14.81 -8.24% -8.98% 220K
|
Transportation and Warehousing
|
| O: -5.17%
H: 36.36%
C: 21.82%
sbi-100 review positive bioscience ophthalmic emulsion phase 1
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Published: 2023-01-09 (Crawled : 22:00) - biospace.com/
ATAI | $1.87 1.08% 1.07% 1M
|
Manufacturing
|
| O: 1.65%
H: 0.54%
C: -10.81%
grx-917 sciences life trial therapeutics positive results phase 1
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2023-01-08 (Crawled : 16:20) - globenewswire.com
VRDN | $14.28 -2.19% -2.24% 810K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
vrdn-001 ongoing thyroid disease eye trial positive phase 1
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
Published: 2023-01-04 (Crawled : 14:20) - prnewswire.com
PULM | $2.015 1.27% 2.0% 8.5K
|
Health Technology
|
| O: -17.61%
H: 13.96%
C: 6.27%
pur3100 migraine positive study phase 1
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
Published: 2022-12-13 (Crawled : 14:00) - globenewswire.com
SLS | $1.54 0.0% 1.5M
|
Health Technology
|
| O: 3.6%
H: 0.39%
C: -6.56%
gfh009 positive phase 1
Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
Published: 2022-12-13 (Crawled : 01:00) - prnewswire.com
PGEN | $1.38 3.76% 3.62% 890K
|
Health Technology
|
| O: 6.83%
H: 1.74%
C: -4.07%
prgn-3006 day leukemia positive acute myeloid leukemia phase 1
Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
Published: 2022-12-10 (Crawled : 00:20) - prnewswire.com
SNDX | $20.97 0.82% 0.81% 670K
|
Health Technology
| Email alert
Add to watchlist
gment-101 meeting trial positive phase 1
Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers
Published: 2022-12-05 (Crawled : 14:20) - biospace.com/
LBPH | $18.67 7.05% 6.69% 480K
|
Manufacturing
|
| O: -3.75%
H: 3.0%
C: -5.0%
lp352 pharmaceuticals system topline positive study phase 1
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
Published: 2022-11-28 (Crawled : 12:20) - globenewswire.com
NBRV | $1.42 1.39% 720K
|
Health Technology
|
| O: 5.53%
H: 25.33%
C: -9.17%
xenleta fibrosis topline trial therapeutics positive results cystic fibrosis phase 1
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
Published: 2022-11-14 (Crawled : 13:00) - globenewswire.com
DARE | $0.2953 5.46% 4.5% 150K
|
Health Technology
|
| O: -0.34%
H: 5.74%
C: 3.7%
topline positive bioscience results study phase 1
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
VRDN | $14.28 -2.19% -2.24% 810K
|
Health Care and Social Assistan...
|
| O: -2.49%
H: 6.5%
C: 1.6%
vrdn-001 ongoing thyroid disease eye trial positive phase 1
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
Published: 2022-11-10 (Crawled : 07:00) - globenewswire.com
MOLN | $3.88 16.87% -3.54% 3.4K
|
Professional, Scientific, and T...
|
| O: 2.15%
H: 1.7%
C: -3.16%
mp0317 treatment ongoing trial tumors positive molecular phase 1
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
Published: 2022-11-07 (Crawled : 13:00) - biospace.com/
RLYB | News | $1.79 1.7% 1.68% 270K
|
|
| O: -1.16%
H: 18.19%
C: 5.28%
rlyb116 positive phase 1
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
Your saved searches
Save your searches and get alerts when important news are released.